Single Ultra-high Dose Stereotactic Body Radiation Therapy for Early Lung Cancer
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorPeking University Third Hospital
About this trial
The goal of this prospective single-arm phase II study is to study the efficacy and safety of stereotactic body radiotherapy (SBRT) for early lung cancer. The main questions it aims to answer are:
How effective is this regimen of SBRT for early lung cancer? How safe is this regimen of SBRT for early lung cancer?
Eligibility criteria
Qualifiers
Signed written informed consent;
Male or female aged ≥ 18 years and ≤ 75 years;
patients with early stage lung cancer confirmed by pathology or clinical MDT;
The physical state score (ECOG PS) of the eastern tumor cooperative group was 0 ~ 1;
Disqualifiers
currently participating in an interventional clinical trial;
any unstable systemic disease, including but not limited to active infection, congestive heart failure [New York Heart Association (NYHA) class ≥ II], severe arrhythmia requiring medical therapy, liver, kidney, or metabolic disease; Type I and type II respiratory failure;
other malignancies within 5 years before randomization, except adequately treated cervical carcinoma in situ, basal cell or squamous skin cancer, local prostate cancer after radical surgery, ductal carcinoma in situ after radical surgery, or papillary thyroid cancer;
women who are pregnant or breastfeeding or who plan to become pregnant or breastfeeding during the study period;
Trial design
Treatments tested in this trial
- SBRT
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov